(Q39742346)

14 September 2017

title

Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment (English)

1 reference

14 September 2017

0 references

1 reference

M Takeuchi

1

1 reference

14 September 2017

S Kimura

2

1 reference

14 September 2017

J Kuroda

3

1 reference

14 September 2017

E Ashihara

4

1 reference

14 September 2017

M Kawatani

5

1 reference

14 September 2017

H Osada

6

1 reference

14 September 2017

K Umezawa

7

1 reference

14 September 2017

E Yasui

8

1 reference

14 September 2017

M Imoto

9

1 reference

14 September 2017

T Tsuruo

10

1 reference

14 September 2017

A Yokota

11

1 reference

14 September 2017

R Tanaka

12

1 reference

14 September 2017

R Nagao

13

1 reference

14 September 2017

T Nakahata

14

1 reference

14 September 2017

Y Fujiyama

15

1 reference

14 September 2017

T Maekawa

16

1 reference

14 September 2017

publication date

5 February 2010

1 reference

Cell Death & Differentiation

14 September 2017

published in

1 reference

14 September 2017

volume

17

1 reference

14 September 2017

issue

7

1 reference

14 September 2017

page(s)

1211-1220

1 reference

14 September 2017

cites work

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Dynamics of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

The tumour microenvironment as a target for chemoprevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Why do cancers have high aerobic glycolysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Tumor microenvironment and the response to anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Targeting hypoxia tolerance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

The Ki-67 protein: from the known and the unknown

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Bone-marrow haematopoietic-stem-cell niches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Reversal of anticancer drug resistance by COTC based on intracellular glutathione and glyoxalase I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Hypoxia modifies proliferation and differentiation of CD34(+) CML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Severe hypoxia defines heterogeneity and selects highly immature progenitors within clonal erythroleukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Loss of Mcl-1 protein and inhibition of electron transport chain together induce anoxic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

On the Origin of Cancer Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Glycolysis inhibition for anticancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

7 January 2021

Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

7 January 2021

Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

7 January 2021

Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

7 January 2021

Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.

1 reference

https://api.crossref.org/works/10.1038%2FCDD.2010.6

7 January 2021

Identifiers

DOI

10.1038/CDD.2010.6

1 reference

14 September 2017

1 reference